<DOC>
	<DOCNO>NCT00198588</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety argatroban patient heparin-induced thrombocytopenia ( HIT ) / HIT thrombosis syndrome ( HITTS ) . This multi-center trial cover mainly patient cardiovascular disease . Subjects include trial clinically diagnose HIT/HITTS . Initial dose argatroban 0.7μg/kg/min , one-third approve dose US . The reason lower initial dose approve dose argatroban Japan ( treatment ischemic stroke ) 0.7μg/kg/min safety high dose drug confirm . A sub-study pharmacokinetics simultaneously conduct reveal relationship among dose , aPTT , blood drug concentration .</brief_summary>
	<brief_title>Efficacy Safety Study Argatroban Treat Heparin-Induced Thrombocytopenia</brief_title>
	<detailed_description />
	<mesh_term>Thrombocytopenia</mesh_term>
	<mesh_term>Argatroban</mesh_term>
	<mesh_term>Calcium heparin</mesh_term>
	<mesh_term>Heparin</mesh_term>
	<criteria>1 . Males nonpregnant female &gt; =20 &lt; =80 year age 2 . Those diagnosis HIT HITTS make follow diagnostic criterion , positive result HIT antibody diagnostic criterion HIT fall platelet count less 100,000/μL 50 % decrease platelets initiation heparin therapy apparent explanation HIT diagnostic criterion HITTS meet diagnosis criterion HIT presence arterial venous thrombosis document appropriate imaging technique ( ultrasound , angiography etc . ) support clinical evidence myocardial infarction , stroke , pulmonary embolism , clinical indication vascular occlusion ( absence pulse , cold , cyanotic extremity , etc . ) patient history HIT/HITTS positive test result ( HIT antibody platelet function test ) could enrol without present thrombocytopenia 3. patient willing able give inform consent 1. condition investigator 's opinion , contraindicate use argatroban endanger patient participate trial 2. clinically significant uncontrolled endocrine , renal , pulmonary , gastrointestinal , psychiatric disorder sufficient severity investigator deem antithrombotic therapy argatroban contraindicate 3. unexplained aPTT &gt; 200 % control baseline 4. documented coagulation disorder unexplained bleed diathesis unrelated HIT 5. lumbar puncture within past 7 day 6. known clinical site bleeding . Patients know site clinical bleeding could enrol investigator deem risk continue thrombosis outweigh potential bleeding risk 7. serious liver disfunction 8. female know suspected pregnancy 9. breast feeding females 10. participation clinical drug trial within past 30 day 11. history hypersensitivity argatroban 12. concomitant use cimetidine 13. previous participation trial</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>November 2008</verification_date>
	<keyword>heparin-induced thrombocytopenia</keyword>
	<keyword>argatroban</keyword>
	<keyword>cardiac surgery</keyword>
	<keyword>acute coronary syndrome</keyword>
	<keyword>thrombosis</keyword>
	<keyword>amputation</keyword>
	<keyword>anticoagulation</keyword>
</DOC>